At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses treatment options for patients with relapsed MM, including anti-CD38 antibodies, cyclophosphamide-based combinations, and BCL-2 inhibitors.
At the 2023 Great Debates &...